Answers are grounded in this paper and cite their sources.
Real-world evidence on ropeginterferon alfa-2 b (ropeg-IFN) in polycythemia vera (PV) remains limited, particularly regarding hematologic effectiveness, treatment modifications, tolerability, and discontinuation outside clinical trials. We conducted a retrospective, single-center study of consecutive patients treated with ropeg-IFN. All treated patients were included in the safety analyses, whereas effectiveness and exploratory association analyses were restricted to patients with definitively adjudicated PV. Complete hematologic response (CHR), disease progression, and toxicity-related treatment discontinuation were evaluated using competing-risk methods. Among 42 treated patients, 34 had definitive PV. Over a median follow-up of 26.5 months, the cumulative incidence of CHR was 43.3% at 12 months and 60.7% at 24 months. Median phlebotomy requirements decreased from three procedures during the pretreatment trimester to 0.5 during the first treatment trimester ( P < 0.001). Overall, 23 patients (54.8%) experienced at least one treatment-emergent adverse event, and six (14.3%) permanently discontinued treatment because of treatment-related toxicity. The cumulative incidence of toxicity-related discontinuation reached 15.9% by 6 months and remained unchanged through 24 months, indicating that treatment-limiting toxicity was concentrated early during therapy. A de-escalated maintenance regimen was implemented in 12 responders, and a treatment-free interval was sustained in three selected patients. Six patients experienced disease progression. Exploratory association analyses were limited by the small number of events and yielded potentially unstable estimates susceptible to sparse-data bias and overfitting. Although higher baseline and time-updated neutrophil-to-lymphocyte ratio values were associated with progression, within-patient changes did not provide additional prognostic information beyond baseline NLR. In routine clinical practice, ropeg-IFN provided progressive hematologic control and substantially reduced phlebotomy requirements in patients with definitive PV. Treatment-limiting toxicity occurred predominantly during the first 6 months, supporting careful monitoring during treatment initiation and dose titration. The progression-related analyses were exploratory and do not establish independent prognostic factors or validate serial NLR monitoring. Larger multicenter studies with longer follow-up are needed to confirm these observations.
No takes yet. Share an insight, caveat, or question.
Thomopoulos et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: